(0.00%) 5 187.67 points
(0.44%) 39 056 points
(-0.18%) 16 303 points
(0.37%) $79.28
(-0.23%) $2.18
(-0.28%) $2 315.90
(-0.22%) $27.54
(0.00%) $984.60
(0.06%) $0.931
(0.13%) $10.90
(0.04%) $0.800
(0.01%) $91.74
Quarter results today
(bmo 2024-05-09)
Expected move: +/- 13.76%
-5.01% $ 6.45
@ $9.20
Emitido: 15 mar 2024 @ 15:39
Retorno: -29.89%
Señal anterior: mar 15 - 09:44
Señal anterior:
Retorno: 0.77 %
Live Chart Being Loaded With Signals
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases...
Stats | |
---|---|
Volumen de hoy | 2.38M |
Volumen promedio | 2.25M |
Capitalización de mercado | 443.80M |
EPS | $0 ( 2024-05-02 ) |
Próxima fecha de ganancias | ( $-0.410 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.42 |
ATR14 | $0.0150 (0.23%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-14 | Mossler Mark | Buy | 27 430 | Stock Option (Right to Buy) |
2024-02-14 | Mossler Mark | Buy | 18 290 | Common Stock |
2024-04-01 | Anderson Kenneth Carl | Buy | 1 389 | Common Stock |
2024-04-01 | Dubin Glenn | Buy | 1 358 | Common Stock |
2024-04-01 | Grogan Donna Roy | Buy | 1 697 | Common Stock |
INSIDER POWER |
---|
59.64 |
Last 98 transactions |
Buy: 4 435 645 | Sell: 1 001 966 |
Volumen Correlación
C4 Therapeutics, Inc. Correlación
10 Correlaciones Más Positivas | |
---|---|
QRTEA | 0.96 |
PTRA | 0.959 |
EIGR | 0.957 |
STIM | 0.957 |
ASPU | 0.955 |
SSP | 0.955 |
MDRX | 0.954 |
AKTX | 0.954 |
PRCH | 0.954 |
PSTX | 0.952 |
10 Correlaciones Más Negativas | |
---|---|
STAY | -0.951 |
CCRC | -0.95 |
SGEN | -0.947 |
PAE | -0.944 |
EBSB | -0.94 |
PTOC | -0.931 |
DSPG | -0.93 |
PPYAU | -0.929 |
RAM | -0.92 |
LMNR | -0.918 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
C4 Therapeutics, Inc. Correlación - Moneda/Commodity
C4 Therapeutics, Inc. Finanzas
Annual | 2023 |
Ingresos: | $20.76M |
Beneficio Bruto: | $13.02M (62.72 %) |
EPS: | $-2.67 |
FY | 2023 |
Ingresos: | $20.76M |
Beneficio Bruto: | $13.02M (62.72 %) |
EPS: | $-2.67 |
FY | 2022 |
Ingresos: | $31.10M |
Beneficio Bruto: | $23.52M (75.65 %) |
EPS: | $-2.59 |
FY | 2021 |
Ingresos: | $45.79M |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-1.730 |
Financial Reports:
No articles found.
C4 Therapeutics, Inc.
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico